Long-Term Outcomes of Pegcetacoplan for GA Show Promise : vi

Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.

Related Keywords

Washington , United States , Seattle , California , American , Roger Goldberg , American Society Of Retina Specialists , Bay Area Retina Associates In Pleasanton , Apellis Pharmaceuticals , American Society , Bay Area Retina Associates , Retina Specialists , Presented July , Exudative Age Related Macular Degeneration , Xudative Armd , Phakic Iol , Phakic Intraocular Lens , Hakic Intraocular Lens Implant , Hakic Iol Implant , Retinal Disease , Vision Care And Maintenance , Retina , Uveitis , Vasculitis , Intraocular Inflammation , Eye , Optic Neuropathy , Corneal Disease , Endophthalmitis , Fundus , Macular Degeneration , Ge Related Macular Degeneration Armd , Neuropathy , Optic Disk , Vegf Vascula ,